Information for patients on availability of new weight loss treatment 💉:
From Monday 23 June, a new weight loss drug called Tirzepatide, sometimes referred to as Mounjaro®, will start becoming available for use in primary care settings.
In line with NHS England guidance, this treatment will only be available for patients who have a body mass index (BMI) above 40 and have been diagnosed with four or more of the following conditions:
- Type 2 diabetes
- Hypertension
- Cardiovascular disease
- Obstructive sleep apnoea
- Dyslipidaemia
Access will be prioritised for those with the greatest clinical need, as the treatment is intended to support people living with health conditions caused or made worse by obesity.
Bath and North East Somerset, Swindon and Wiltshire Integrated Care Board is currently working with colleagues in primary care to ensure this new treatment is offered to those patients who fulfil this criteria.
At this time, patients are kindly asked not to contact their GP practice with requests for weight loss treatment
All patients, including those who may be eligible for the new drug, are continued to be encouraged to access NHS-supported healthy living initiatives, such as diet support and activity groups, as part of their overall weight loss journey.